SS&C Technologies (SSNC) Q3 2026 Earnings: Why Net Income Fell as Operating Income Rose 11.9%
Listen to this report
SS&C Technologies $SSNC grew operating income 11.9% in the third quarter of 2026, to $409.3M, and still reported net income 5.3% lower than a year earlier: $198.9M against $210.0M. The gap is one line below operating income. Equity in earnings of unconsolidated affiliates swung to a $47.7M loss, and $47.6M of it came from Orbit Private Investments L.P., a fund in which SS&C holds 9.8%. The 10-Q's MD&A calls it only "one of our investments". The adjusted EPS of $1.78 in SS&C's October 22 earnings release (8-K) adds the whole $47.7M back.
That matters because Earnings Whispers (October 22) and StockStory (October 23) wrote the quarter up as a story about organic growth slowing and AI pressure on Blue Prism. The operating business did fine. What kept GAAP diluted EPS flat at $0.83 was a passive stake that has gone from a $96.3M contributor in 2023 to a $43.1M drag in the first nine months of 2026, and a share count that did more of the per-share work than the headline suggests.
Company Snapshot
SS&C calls itself a global provider of investment, financial and healthcare technology and technology-enabled services. Most of its revenue is the second part: software it runs for clients as a service, such as fund administration, rather than licenses it sells. It reports one segment, and its chief operating decision maker judges that segment on consolidated net income, the line that fell. This brief reads the 10-Q for the quarter ended September 30, 2026 (accession 0001193125-26-453587, filed November 9, 2026), the October 22 earnings release (8-K) and the November 9 8-K on the refinancing, with history from the FY2025 10-K.
The Financial Story
The top line was two businesses moving apart. Revenue rose 7.8% to $1,690.0M. Technology-enabled services, 86% of revenue, grew 10.6% to $1,448.6M. License, maintenance and related revenue fell 6.7% to $241.4M, and inside it perpetual licenses dropped to $1.7M from $13.2M. The October 22 earnings slides (8-K) show adjusted organic revenue down 4.5% in Intelligent Automation & Analytics, a unit that includes Blue Prism, Regulatory Solutions and Algorithmics, and guide Q4 organic growth to 4.0% at the midpoint. The services side is where the growth is, and it carries the margin: operating margin rose to 24.2% from 23.3%.
| Q3 (USD M) | 2026 | 2025 | Change |
|---|---|---|---|
| Revenue | $1,690.0 | $1,568.0 | +7.8% |
| Operating income | $409.3 | $365.7 | +11.9% |
| Equity in earnings of affiliates | $(47.7) | $(11.6) | 4.1x the loss |
| Income before taxes | $256.7 | $253.9 | +1.1% |
| Provision for income taxes (charged) | $58.6 | $43.5 | rate 22.8% vs 17.1% |
| Net income to SS&C | $198.9 | $210.0 | -5.3% |
| Diluted EPS | $0.83 | $0.83 | flat |
Below operating income, two things ate the gain. Pretax income excluding the affiliate line rose 14.7%, to $304.4M from $265.5M. The Orbit markdown took that to 1.1%. Then the tax charge rose to a 22.8% rate from 17.1%, which the 10-Q attributes to prior-year releases of uncertain tax positions, smaller stock-award windfalls and the mix of income by country. That is tax charged, an accrual; the 10-Q does not disclose cash taxes paid for the quarter (for FY2025 the 10-K shows $176.1M charged and $219.4M paid).
Orbit is a small asset with a large swing. The FY2025 10-K describes Orbit Private Investments as "a provider of shareholder and pension technology" and says SS&C books its share on a three-month lag. The stake was carried at $202.9M at the end of 2025 and $142.9M on September 30, 2026: down 29.6%, from the $43.1M nine-month loss plus a $16.9M distribution. Its contribution has gone $96.3M (2023), $19.1M (2024), a $10.6M loss (2025), a $43.1M loss (nine months of 2026). One quirk: the FY2025 10-K's XBRL tags that 2025 figure as a positive $10.6M while its own table shows a loss, so anyone pulling the tag without reading the table gets the sign wrong. With $142.9M left on the books, the drag has a ceiling, but the line is not noise either: it equals nearly a fifth of the quarter's pretax income.
The per-share story leans on buybacks, which slowed. Adjusted net income to SS&C rose 9.6% to $429.0M; diluted shares fell 4.8% to 240.6M; adjusted EPS rose 14.8%. About a third of the growth came from the share count. The timing of the buyback is the second thing the filings show.
| Buybacks (incl. 1% excise) | Shares | Cost | Avg price |
|---|---|---|---|
| Q1 2026 | 2.3M | $168.4M | n/a |
| Q2 2026 | 6.4M | $439.5M | about $68 |
| Q3 2026 | 1.9M | $154.8M | about $80 |
| Nov 2026 (convert proceeds) | about 1.3M | about $100.0M | $79.57 |
SS&C bought hardest in Q2, near $68, and eased off as the stock ran toward $80. For nine months, buybacks of $760.5M and dividends of $199.8M came to $960.3M against free cash flow of $989.1M (operating cash flow of $1,216.3M less $37.0M of capex and $190.2M of capitalized software). Option-exercise proceeds, which helped fund 2025, fell to $86.0M from $362.4M. Returns now absorb nearly all of free cash flow, and $1,114.7M of authorization remained at September 30.
The refinancing is cheaper on coupon and adds a dilution tail. The October 22 release showed $2,260.0M of debt due within a year, which is where Earnings Whispers' October 22 line that the notes were "now classified current" came from. The 10-Q, filed after the deals closed on November 6, shows $260.0M current and classifies the $2,000.0M of 5.5% notes due 2027 as long-term, because the money to redeem them is in hand: $1,200.0M of 2.75% convertible notes due 2031 (conversion price about $99.46), $750.0M of incremental Term B-8 loans and $240.0M of Term A-9 loans, with the revolver raised by $400.0M and extended to November 2031. Swapping a 5.5% coupon on $2B for 2.75% on $1.2B cuts fixed coupon cost, though the term loans float. The capped calls cost $112.8M and $100.0M went to buy back shares, so part of the "refinancing" was a leveraged buyback. Net debt at September 30 was $6,924.1M (carrying debt of $7,449.5M less $525.4M of cash), 2.63x by the credit agreement's measure.
Valuation: what it's worth as a normal business
Where it trades. At $74.15 (stockanalysis.com, November 20 close), the 234.8M shares on the 10-Q cover give a market value of $17.4B and, with $6.9B of net debt, an enterprise value near $24.3B. That is 10.4x the midpoint of SS&C's FY2026 adjusted EPS guidance ($7.11-$7.17) and 21.4x trailing earnings by stockanalysis.com's count, read November 21. The 10 analysts stockanalysis.com tracked on November 21 rate it a Buy with an average target of $98.56. Screens on vcpscanner and Seeking Alpha, read November 21 and not dated by either site, put Broadridge near 16-17x forward earnings, SEI near 15x and FIS near 7.5x.
Scenario DCF. The base is SS&C's own FY2026 guide: operating cash flow of $1,717-$1,817M less capex of 4.4%-4.8% of revenue, about $1,456M of free cash flow at the midpoints. Five years of growth, then 3% terminal growth, discounted at the house 9%, less $6.9B of net debt, over 234.8M shares:
| Scenario | FCF growth, years 1-5 | Implied value per share |
|---|---|---|
| Bear | 0% | $64 |
| Base | 5% | $87 |
| Bull | 8% | $102 |
Peer re-rating. On the $7.14 adjusted EPS midpoint, 8x (FIS-like) implies $57, 12x implies $86, and 16x (Broadridge-like) implies $114. Adjusted EPS excludes $62.1M a quarter of stock-based compensation, a real cost, so the low end of that grid deserves more weight than the high.
What the price implies. $74.15 equals free cash flow growing about 2.4% a year for five years, under the same assumptions. That is below the 5.2% adjusted organic growth SS&C reported for Q3 and under the 4.0% Q4 organic midpoint in its October 22 guidance (8-K). On these assumptions the price does not pay for the buyback math; it prices a slowdown. Implied value under stated assumptions, not a price target and not investment advice.
Risks
Organic growth is decelerating, and license revenue, where Blue Prism sits, is shrinking. Per StockStory on October 23, CEO Bill Stone said contracts can now run "$2.5-5 billion and up" and that getting them live is the gating factor, so timing can move revenue between quarters. The Orbit stake can still lose up to its $142.9M carrying value, and it reports on a lag. The new term loans float. The capped calls offset dilution from the convertible between its conversion price of about $99.46 and a cap of about $139.25 (November 9 8-K); above the cap, conversion dilutes. With returns near 100% of free cash flow, any cash shortfall comes out of the buyback, which supplied about a third of adjusted EPS growth this quarter.
The Bottom Line
SS&C's operating business grew earnings faster than revenue this quarter: operating income up 11.9%, margin up to 24.2%. The GAAP decline came from a 9.8% stake in Orbit, marked down $47.6M and now carried at $142.9M, and from a higher tax charge, and the adjusted EPS headline adds the markdown back. Watch three things in Q4: whether Orbit marks down again, whether the $2B redemption closes as Note 14 says, and whether buybacks hold near $80 once the convert-funded $100M is spent. At 10.4x adjusted guidance, the price assumes growth slows to around 2%. That is not much to ask of a business still compounding services revenue at 10%.
Nobody wrote this by hand. Every number about SS&C's own results came out of its SEC filings (the 10-Q, two 8-Ks and the 10-K), read line by line by software; the share price, analyst and peer figures are web data, named and dated where they appear. The same reading works on any company that files XBRL with the SEC, including a fund in the footnotes like Orbit.
Numbers from SS&C's SEC filings via RoboSystems. Market data attributed and dated in the text.
Ask the filing yourself
Every figure in this report came from SS&C Technologies Holdings, Inc.'s SEC filings in the RoboSystems SEC Shared Repository. Connect it to Claude or ChatGPT and ask your own questions, starting with this one:
How much did Orbit Private Investments cost SS&C in equity-method earnings in Q3 2026, and what is the stake carried at now?